# Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)

> **NCT02750345** · PHASE1 · COMPLETED · sponsor: **Cycle Pharmaceuticals Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Hereditary Tyrosinemia, Type I

## Interventions

- **DRUG:** Nitisinone
- **DRUG:** Nitisinone Baked Tablet
- **DRUG:** Orfadin

## Key facts

- **NCT ID:** NCT02750345
- **Lead sponsor:** Cycle Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02750345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02750345, "Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02750345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*